Title

PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
A Multi-centre, Open-label, Uncontrolled, First-in-Human Study to Evaluate the Safety and Tolerability and Explore the Efficacy of PeproStat in Gelita-Spon® Gelatin Sponge in Subjects Undergoing Open Liver Resection Surgery
  • Phase

    Phase 1
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    peprostat ...
  • Study Participants

    20
The purpose of this First in Man study is to evaluate the safety and tolerability, as well as to explore efficacy of PeproStat, a new peptide based coagulant (haemostat), when used in patients undergoing open liver resection surgery.
Study Started
Jul 31
2014
Primary Completion
Sep 30
2015
Study Completion
Sep 30
2015
Last Update
Oct 21
2015
Estimate

Drug PeproStat

A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.

Haemostat Experimental

PeproStat

Criteria

Inclusion Criteria:

Are able and willing to provide written informed consent to participate in this study, confirmed by signing the informed consent documents
Adult males and females ≥18 years of age
Female subjects must be post-menopausal. Post-menopausal status is defined as any of the following: natural menopause with menses >1 year ago; radiation induced oophorectomy with last menses >1 year ago; chemotherapy induced menopause with 1 year interval since last menses
Willing and able to comply with all protocol requirements including follow-up
Subject must have a haemoglobin ≥ 9.0 g/dL at screening
Subject must have a platelet count ≥ 100,000/mm3 at screening
Subject is undergoing a planned open liver resection
Male subjects must be willing and able to use adequate contraception from enrollment through to the 30 day follow-up visit
During the surgery, the subject presents an identified target bleeding site (TBS) with oozing, mild or moderate bleeding, which conventional surgical techniques are insufficient to control and would otherwise be a candidate for standard haemostats
During the surgery, subject presents no intraoperative complications, other than bleeding, that may interfere with study assessments as judged by the investigator

Exclusion Criteria:

Subject is undergoing emergency surgical procedure
Recipient of a liver transplant
Females of child-bearing potential
Active infection at the time of the liver resection
International Normalized Ratio (INR) > 2.0 or APTT ratio > 2.0 at screening
Fibrinogen level < 1.5g/L at screening
History of thromboembolic disease and/or thrombophilia
Any other disease or condition that may affect normal blood clotting, for example thrombocytopenia, as judged by the investigator
A known history of anaphylaxis or allergic reaction to human albumin, PEGylated proteins, yeast or moulds, porcine products or other components in the IMP
Participation in another investigational drug or device research study within 30 days before and after enrolment in the current study
Current known or suspected alcohol and/or drug abuse or dependence at the time of screening
Any concurrent medical, surgical, or psychiatric condition that may, in the investigator's opinion, affect the subject's willingness or ability to meet all study requirements during the study duration
During the surgery, subject presents severe bleeding where use of a topical haemostat would be inappropriate
Subject is taking any prohibited medications
BMI at screening of ≥35
No Results Posted